An economic evaluation of intensive hypertension control in CKD patients: a cost-effectiveness study
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background: Studies have suggested that intensive hypertension control in patients with a high risk of cardiovascular disease (CVD) is both effective and economically feasible. The purpose of this study is to conduct an economic evaluation of intensive hypertension control targeting chronic kidney disease (CKD) patients using the representative data in Korea. Methods: We used a Markov decision model to compare both cost and effectiveness of intensive hypertension control versus standard hypertension control in hypertensive CKD patients. Model parameters were estimated with the data from the National Health Insurance Service (NHIS)-National Sample Cohort, as well as latest literature. One-way sensitivity analysis was conducted to test the effect of variation in key parameters on the model outcome. Results: For CKD patients with hypertension, intensive hypertension control would cost more but increase utilities, compared to standard hypertension control. The incremental cost-effectiveness ratio (ICER) for intensive hypertension control in CKD patients was projected at 18,126 USDs per quality-adjusted life year (QALY) compared to standard hypertension control. The results of sensitivity analysis suggest that the results are overall robust. Conclusions: This study finds that intensive hypertension control in CKD patients in Korea is economically sound. This information is expected to be useful for clinicians in managing hypertension of CKD patients and policymakers when making decisions.
Abstract
Background: Studies have suggested that intensive hypertension control in patients with a high risk of cardiovascular disease (CVD) is both effective and economically feasible. The purpose of this study is to conduct an economic evaluation of intensive hypertension control targeting chronic kidney disease (CKD) patients using the representative data in Korea. Methods: We used a Markov decision model to compare both cost and effectiveness of intensive hypertension control versus standard hypertension control in hypertensive CKD patients. Model parameters were estimated with the data from the National Health Insurance Service (NHIS)-National Sample Cohort, as well as latest literature. One-way sensitivity analysis was conducted to test the effect of variation in key parameters on the model outcome. Results: For CKD patients with hypertension, intensive hypertension control would cost more but increase utilities, compared to standard hypertension control. The incremental cost-effectiveness ratio (ICER) for intensive hypertension control in CKD patients was projected at 18,126 USDs per quality-adjusted life year (QALY) compared to standard hypertension control. The results of sensitivity analysis suggest that the results are overall robust. Conclusions: This study finds that intensive hypertension control in CKD patients in Korea is economically sound. This information is expected to be useful for clinicians in managing hypertension of CKD patients and policymakers when making decisions.
참고문헌 (13)
- 김현창, "Korea hypertension fact sheet 2020: analysis of nationwide population-based data", Clinical Hypertension, 27(2), pp.66~69 (2021), 대한고혈압학회[DOI]
- Anderson AH, "Time-updated systolic blood pressure and the progression of chronic kidney disease : a cohort study", Ann Intern Med, 162, pp.258~265 (2015)
- Go AS, "Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization", N Engl J Med, 351, pp.1296~1305 (2004)
- Bakris GL, "The message for World Kidney Day 2009 : hypertension and kidney disease : a marriage that should be prevented", Kidney Int, 75, pp.449~452 (2009)
- Group SR, "A randomized trial of intensive versus standard blood-pressure control", N Engl J Med, 373, pp.2103~2116 (2015)
- Xie X, "Effects of intensive blood pressure lowering on cardiovascular and renal outcomes : updated systematic review and meta-analysis", Lancet, 387, pp.435~443 (2016)
- Cheung AK, "Effects of Intensive BP Control in CKD", J Am Soc Nephrol, 28, pp.2812~2823 (2017)
- Moise N, "Comparative Cost-effectiveness of conservative or intensive blood pressure treatment guidelines in adults aged 35–74 years : the cardiovascular disease policy model", Hypertension, 68, pp.88~96 (2016)
- Richman IB, "Cost-effectiveness of intensive blood pressure management", JAMA Cardiol, 1, pp.872~879 (2016)
- Xie X, "Cost-effectiveness analysis of intensive hypertension control in China", Prev Med, 111, pp.110~114 (2018)
- Sullivan PW, "Preference-based EQ-5D index scores for chronic conditions in the United States", Med Decis Making, 26, pp.410~420 (2006)
- Kim S, "Cost-effectiveness of an opioid abuse-prevention program using the narcotics information management system in south Korea", Value Health, 24, pp.174~181 (2021)
- Moran AE, "Cost-effectiveness of hypertension therapy according to 2014 guidelines", N Engl J Med, 372, pp.447~455 (2015)